Artificial Pancreas Device Systems Market

Global Artificial Pancreas Device Systems Size (2022 to 2027)

The size of the artificial pancreas device systems market at a global level is expected to reach USD 402 million by 2027, growing at a CAGR of 15.5% from 2022 to 2027.

The artificial pancreas device is a boon for diabetic patients as they process to provide a healthy pancreas by substituting endocrine functionality. The hormones insulin and glucagon are provided by islet cells in the pancreas, allowing proper functioning of the brain, liver, and kidneys.

Impact of COVID-19 on the global artificial pancreas device systems market:

The artificial pancreas device systems market is analyzed to witness substantial growth post-pandemic. However, COVID-19 has affected global economies and various industries due to lockdowns, travel bans, and shutting down manufacturing units. As the COVID-19 pandemic progresses, the healthcare sector is expected to experience a decline in market growth due to a decrease in sales from a decline in the number of surgeries performed and delayed or prolonged equipment supplies. Additionally, the halt in clinical trials and subsequent delay in drug launches are also estimated to pave the way for virtual trials in the future. New technologies such as mRNA intend to emerge and change the pharmaceutical sector, and the market is also expected to experience more joint ventures in the coming years.

MARKET DRIVERS:

The large diabetic population and the increasing prevalence of diabetes is the main reason for increasing the demand for an artificial pancreas device system (APDS) market during the forecast period.

According to the International Diabetes Federation (IDF), in 2021, more than 537 million adults (20-79 years old) worldwide will be living with diabetes globally. The total number of people living with diabetes is estimated to reach 643 million by 2030 and 783 million by 2045. Low- and middle-income countries are the most affected, particularly in Asia, Africa, and Latin America. The rising prevalence of pancreatic cancer, pancreatitis, and other chronic conditions also drives the market. In addition, the increasing incidence of obesity due to age-related factors, physical inactivity, and unhealthy eating habits are also contributing to the widespread adoption of APDS in the world.

APDS automatically monitors glucose levels and delivers insulin doses throughout the day in controlled amounts. Almost 1 in 2 adults (240 million) live with diabetes and are undiagnosed. In 2021, approximately 6.7 million deaths were due to diabetes. Hence, the use of APDS will decrease the death rate and complications in diabetic patients across the globe. There is a massive requirement for an effective and long-lasting alternative drug that can substitute insulin. However, type 2 diabetes can be well controlled in most patients with oral medications, but people with type 1 diabetes should use insulin first. Various technological innovations, including the development of software-based wireless systems that integrate with automated controls, further contribute to the market's growth. At least US$966 billion in healthcare spending was spent on diabetes in 2021, including 9% of total spending for adults.

More than 10% of the diabetic population is affected by type 1 diabetes. People with type 1 diabetes need to inject insulin daily to control their blood sugar and symptoms. In addition, worldwide, more than 1.2 million children and adolescents (0-19 years old) live with type-1 diabetes. Thus, it increases the demand for APDS and further drives the market's growth. Growing demand for effective minimally invasive (MI) diabetes monitoring and drug delivery systems is also driving the market growth.  Local governments in many countries are investing heavily in research and development (R&D) to improve healthcare infrastructure worldwide.

MARKET RESTRAINTS:

However, certain restraints and difficulties encountered may hinder the growth of the artificial pancreas device system market, such as the lack of trained professionals in underdeveloped regions like Africa and South America and limited resources for research and development.

REPORT COVERAGE:

This research report on the global artificial pancreas device systems market has been segmented and sub-segmented based on type, end-user, and region.

Artificial Pancreas Device Systems Market - By Type:

• Control to Range
• Control to Target Systems

In 2021, the control-to-target system segment held the largest market share, and this segment will also grow with the highest CAGR during the forecasted timeline. The CTT system is anticipated to witness the fastest growth with a healthy CAGR. CTT system is a fully automated system that minimizes patient intervention, and this factor will contribute to the market growth rate.

Artificial Pancreas Device Systems Market - By End User:

• Hospital
• Medical Centers
• Others

In 2021, the hospital segment was dominating the APDS market share and will continue to lead the market share by 2027. The growth of this segment can be attributed to the growing number of hospitals with the latest adoption of APDS and the presence of skilled labor.

Artificial Pancreas Device Systems Market - By Region:

• North America
  • The U.S.
  • Canada
  • Rest of North America
• Europe
  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Rest of EU
• Asia-Pacific
  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Rest of Latin America
• Middle East
• Africa

In 2021, the regional market in Europe dominated the artificial pancreas device system market, and it is likely to continue the same trend during the assessment period. According to Beyond Type 1, approximately 1.64 million people have type 1 diabetes. In addition, 5 million people are estimated to be diagnosed with type 1 diabetes by 2050. Higher incidence of diabetes will be the primary driver leading the market in this region. According to the Administration of Food and Drug Administration, using an artificial pancreas is associated with better blood sugar control in people with type 1 diabetes than the normal methods. Hence, owing to this factor, major players are increasing funding to develop better and more innovative devices to cater to the growing market demand across European countries.

Over the analysis period, North America is estimated to be a significant market shareholder, owing to various factors such as the rising geriatric population, the high incidence rate of diabetes and its complications, well-developed medical facilities, and technological advancements. According to the Centers for Disease Control and Prevention (CDC) National Diabetes Statistics 2020 report, approximately 34.24 million people of all ages had diabetes in the United States in 2018. The percentage of adults with diabetes has increased with age to reach 26.8% among those over 65. Additionally, nearly 88 million American adults were estimated to have prediabetes in 2018. According to the Institute for Health Metrics and Evaluation, the prevalence rate of diabetes mellitus in 2019 was estimated at 11,847 per 100,000 and 11,366 per 100,000 in 2018 in the U.S. The elderly population is more susceptible to acquiring diabetes with age and preference for a sedentary lifestyle in the region. Based on the Bureau of Population Reference's Aging in America population bulletin, the number of Americans age 65 and older is expected to nearly double, from 52 million in 2018 to 95 million by 2060.

However, the APAC region is projected to witness the fastest growth in the studied market. The development of this regional market is due to factors such as growing demand for APDS in developing countries, increasing healthcare expenditure, and the availability of a large population base. According to an article published by NCBI, Asian countries account for more than 60% of the global diabetic population, driving the growth of the APDS market in the region.

KEY MARKET PLAYERS:

Some of the noteworthy companies that dominate the global artificial pancreas device systems market in this report are Medtronic Plc, Johnson & Johnson, Insulet Corp, Tandem Diabetes Care, F. Hoffmann-La Roche Ltd, Beta Bionics, Bigfoot Biomedical Inc., Inreda Diabetic B.V., Dexcom, Inc., and Cellnovo.

The aforementioned market is highly competitive, with significant players dominating the market. Many small and medium-sized enterprises are also stepping into the artificial pancreas device systems market, leading to impressive growth over the analysis period.